Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDONATION KIDNEY RESERVE
2024-519757-11-00Phase 3Authorised
- Sponsor
- Hospital Universitario de Canarias
- Start
- Dec 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Nephrotect, sponsored by Hospital Universitario de Canarias. Primary endpoint: Evolution of renal function in donor and recipient after renal transplantation. Planned start Dec 2024; status: authorised.
02
Drugs
Nephrotect
Beyond the preview
Go deeper on 2024-519757-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519757-11-00.